Mechanism and function of decreased FOXO1 in renal cell carcinoma

被引:29
作者
Zhou, Libin [1 ]
Yin, Bingde [1 ]
Liu, Yongchao [1 ]
Hong, Yan [1 ]
Zhang, Changcun [1 ]
Fan, Jie [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Urol, Shanghai 200080, Peoples R China
关键词
FOXO1; renal cell carcinoma; miR-27a; proliferation; CANCER-CELLS; PROSTATE-CANCER; TRANSCRIPTION FACTORS; ENDOMETRIAL CANCER; EXPRESSION; TARGET; MICRORNA-27A; ACTIVATION; AKT;
D O I
10.1002/jso.23013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives Forkhead box O-class 1 (FOXO1), a putative tumor suppressor, is dysregulated in many cancers. Our study aims to reveal the underlying functions and regulation mechanisms of FOXO1 in renal cell carcinoma (RCC). Methods The clinical significance of FOXO1 expression in surgically resected specimens was assessed by immunohistochemistry. The siRNAs targeted FOXO1 and miR-27a inhibitor were transfected into RCC cells. QRT-PCR, Western blot, and cell proliferation assay were used to assess the expression and function of FOXO1 and miR-27a. Results The positive immunostaining for FOXO1 was low in 51 RCC samples compared with 15 normal kidney tissues. And the expression of FOXO1 was related with RCC subtypes and the grade and stage in clear cell RCC (cRCC) (P?<?0.05). Inhibition of FOXO1 promoted proliferation of 769-P cells. However, upregulation of FOXO1 by miR-27a inhibitor was accompanied by the anti-proliferative effect in cells of 786-O and Caki-1. Furthermore, the expression of FOXO1 mRNA and miR-27a had inverse relation in eight cRCC samples. Conclusion Reduced expression of FOXO1 is common in RCC and a potentially suitable marker of different histological subtypes and prognosis of cRCC. Increasing expression of FOXO1 by the miR-27a inhibitor could prevent cell growth. J. Surg. Oncol. 2012; 105:841847. (c) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:841 / 847
页数:7
相关论文
共 35 条
  • [31] A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk
    Yang, Rongxi
    Schlehe, Bettina
    Hemminki, Kari
    Sutter, Christian
    Bugert, Peter
    Wappenschmidt, Barbara
    Volkmann, Juliane
    Varon, Raymonda
    Weber, Bernhard H. F.
    Niederacher, Dieter
    Arnold, Norbert
    Meindl, Alfons
    Bartram, Claus R.
    Schmutzler, Rita K.
    Burwinkel, Barbara
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (03) : 693 - 702
  • [32] Understanding FOXO, New Views on Old Transcription Factors
    Zanella, F.
    Link, W.
    Carnero, A.
    [J]. CURRENT CANCER DRUG TARGETS, 2010, 10 (02) : 135 - 146
  • [33] FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion
    Zhang, Haijun
    Pan, Yunqian
    Zheng, Li
    Choe, Chungyoul
    Lindgren, Bruce
    Jensen, Eric D.
    Westendorf, Jennifer J.
    Cheng, Liang
    Huang, Haojie
    [J]. CANCER RESEARCH, 2011, 71 (09) : 3257 - 3267
  • [34] Activation of FOXO1 Is Critical for the Anticancer Effect of Methylseleninic Acid in Prostate Cancer Cells
    Zhang, Haitao
    Fang, Jian
    Yao, Dian
    Wu, Yue
    Ip, Clement
    Dong, Yan
    [J]. PROSTATE, 2010, 70 (12) : 1265 - 1273
  • [35] Akt, FoxO and regulation of apoptosis
    Zhang, Xinbo
    Tang, Naimei
    Hadden, Timothy J.
    Rishi, Arun K.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2011, 1813 (11): : 1978 - 1986